Cosponsored with Funders Concerned About AIDS (FCAA)
This webinar focused on the critical role the 340B Drug Pricing Program plays in financing health services in the United States. For almost 30 years, the 340B program has allowed health care organizations – including small rural hospitals and community health centers – to help low-income and at-risk populations access discounts on medications they provide, and to use the savings to invest in expanded services for patients. The 340B program continues to be at the center of drug pricing reform conversations and is therefore at risk due to proposed changes within state Medicaid programs that may significantly limit or end the benefits received by health care organizations. These resources are particularly crucial in the U.S. South and in states that have not expanded Medicaid. This discussion highlighted both the purpose and vulnerability of the program, the advocacy needed to protect its future, and the important role funders can play in this moment. Speakers included Bill Keeton of Vivent Health, Jeffrey Lewis of the Legacy Health Foundation, Mary Elizabeth Marr of Thrive Alabama, Jesse Milan of AIDS United, and Vacheria Tutson of the National Association of Community Health Centers.